- Title: Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
- Date: 22nd January 2018
- Summary: PARIS, FRANCE (FILE) (REUTERS) VARIOUS OF SANOFI HEADQUARTERS
- Embargoed: 5th February 2018 13:35
- Keywords: Sanofi takeover U.S. haemophilia group Bioverativ for $11.6 billion drugmakers deal flurry
- Location: VARIOUS LOCATIONS
- City: VARIOUS LOCATIONS
- Country: France
- Topics: Company News Markets,Economic Events
- Reuters ID: LVA0067Z71H8T
- Aspect Ratio: 16:9
- Story Text:French healthcare group Sanofi said on Monday (January 22, 2018) that it has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. The move comes at a time of renewed interest by large drugmakers in smaller biotech firms and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.
Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 per share in cash, marking a premium of 64 percent to Bioverativ's closing price on January 19.
Bioverativ, a maker of haemophilia drugs, was separated from Biogen Inc. early last year.
The agreed transaction marks Sanofi's successful return to deal-making after its failure to land major takeovers in recent years. It is its biggest acquisition since the 2011 takeover of U.S. biotech company Genzyme for around $20 billion. - Copyright Holder: FILE REUTERS (CAN SELL)
- Copyright Notice: (c) Copyright Thomson Reuters 2018. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None